[76], which demonstrated for the first time that glioma cells carrying heterozygous IDH1 R132H mutation switch TAMs toward a phagocytic anti‐tumor phenotype by downregulating ICAM1/CD54 pathway. This evidence concerns the gene IDH1 and central nervous system cancer.